Warmuth Markus 4
4 · Monte Rosa Therapeutics, Inc. · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Warmuth Markus
DirectorPresident & CEO
Transactions
- Sale
Common Stock
2026-01-07$23.24/sh−3,707$86,159→ 620,696 total - Sale
Common Stock
2026-01-07$23.88/sh−1,450$34,620→ 619,246 total - Sale
Common Stock
2026-01-07$24.57/sh−309$7,593→ 618,937 total
Footnotes (4)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.